Tandemact
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Pioglitazone;glimepiride
- Made by
- CHEPLAPHARM Arzneimittel GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | CHEPLAPHARM Arzneimittel GmbH |
|---|---|
| Active substance | Pioglitazone;glimepiride |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A10BD06 · Digestion, stomach, diabetes and nutrition |
| Authorised on | 2007-01-08 |
| Last updated by the regulator | 2023-09-13 |
| EMA product number | EMEA/H/C/000680 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).